A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: A pilot study

Fertility and Sterility

Volumn 82, Issue 2, 2004, Pages 421-429

  Hoeger, Kathleen M ^a   Kochman, Lynda ^a   Wixom, Nellie ^b   Craig, Kimberly ^a   Miller, Richard K ^a   Guzick, David S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF NURSING   (United States)

Author keywords

obesity; ovulation; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; GLUCURONIDE; METFORMIN; PLACEBO; PREGNANEDIOL; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG FORMULATION; FEMALE; HUMAN; LIFESTYLE; MEASUREMENT; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SIDE EFFECT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; DOUBLE-BLIND METHOD; ELECTRIC IMPEDANCE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; METFORMIN; OBESITY; PATIENT DROPOUTS; PATIENT SELECTION; PILOT PROJECTS; POLYCYSTIC OVARY SYNDROME; WEIGHT LOSS;

EID: 4143112307     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2004.02.104     Document Type: Article

References (36)

1. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States a prospective study. J Clin Endocrinol Metab. 83:1998;3078-3082
2. Zawadzki J.K., Dunaif A. Diagnositic criteria for polycystic ovary syndrome: towards a rational approach. Dunaif A., Givens J.R., Haseltine F.P., Merriam G.R. Polycystic ovary syndrome. 1992;377-384 Blackwell Scientific, Oxford, United Kingdom
3. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 28:2001;85-97
4. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1989;1165-1174
5. Franks S., Gilling-Smith C., Watson H., Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 28:1999;361-378
6. Dunaif A., Graf M., Mandeli J., Laumas V., Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:1987;499-507
7. Chang R.J., Nakamura R.M., Judd H.L., Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarine disease. J Clin Endocrinol Metab. 57:1983;356-359
8. Dunaif A. Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis. Endocr Rev. 18:1997;774-800
9. Barbieri R.L. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. J Reprod Med. 39:1994;327-336
10. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:1996;617-623
11. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 338:1998;1876-1880
12. Morin-Papunen L.C., Koivunen R.M., Ruokonen A., Martikainen H.K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 69:1998;691-696
13. Fleming R., Hopkinson Z.E., Wallace A.M., Greer I.A., Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind, placebo controlled fashion. J Clin Endocrinol Metab. 87:2002;569-574
14. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:1996;3299-3306
15. Ehrmann D.A., Schneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116
16. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fershetian A.G., et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 86:2001;1626-1632
17. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;524-530
18. Pasquali R., Casimirri F., Venturoli S., Antonio M., Morselli L., Reho S., et al. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism. 43:1994;706-713
19. Guzick D.S., Wing R., Smith D., Berga S.L., Winters S.J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril. 61:1994;598-604
20. Saris W.H. Very-low-calorie diets and sustained weight loss. Obes Res. 9:(Suppl 4):2001;295S-301S
21. Huber-Buchholz M.M., Carey D.G., Norman R.J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 84:1999;1470-1474
22. Pasquali R., Gambineri A., Biscotti D., Vicennati V., Gagliardi L., Colitta D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab. 85:2000;2767-2774
23. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403
24. Taylor R.W., Keil D., Gold E.J., Williams S.M., Goulding A. Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women evaluation using receiver operating characteristic curves. Am J Clin Nutr. 67:1998;44-49
25. Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1961;1440-1447
26. Santoro N., Crawford S.L., Allsworth J.E., Gold E.B., Greendale G.A., Korenman S., et al. Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab. 284:2003;E521-530
27. Legro R.S. Polycystic ovary syndrome. Long term sequelae and management. Minerva Ginecol. 54:2002;97-114
28. Nestler J.E., Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab. 82:1997;4075-4079
29. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 85:2000;139-146
30. Pasquali R., Casimirri F., Colella P., Melchionda N. Body fat distribution and weight loss in obese women. Am J Clin Nutr. 49:1989;185-187
31. Hamilton-Fairley D., Kiddy D., Anyaoku V., Koistinen R., Seppala M., Franks S. Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction. Clin Endocrinol (Oxf). 39:1993;363-367
32. Appel L.J., Champagne C.M., Harsha D.W., Cooper L.S., Obarzanek E., Elmer P.J., et al. Effects of comprehensive lifestyle modification on blood pressure control main results of the PREMIER clinical trial. JAMA. 289:2003;2083-2093
33. Pasanisi F., Contaldo F., de Simone G., Mancini M. Benefits of sustained moderate weight loss in obesity. Nutr Metab Cardiovasc Dis. 11:2001;401-406
34. Thompson P.D., Buchner D., Pina I.L., Balady G.J., Williams M.A., Marcus B.H., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 107:2003;3109-3116
35. Moran L.J., Noakes M., Clifton P.M., Tomlinson L., Norman R.J. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 88:2003;812-819
36. Foster G.D., Wyatt H.R., Hill J.O., McGuckin B.G., Brill C., Mohammed B.S., et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 348:2003;2082-2090